We pushed a 24-hour MinION run last week for a disease cohort pilot, and it raised a practical question: how are you handling consent language around incidental findings when whole-genome reads are generated, and what’s your protocol for de-identification before FASTQ transfer to external teams? We strip PHI, hash sample IDs, and store the re-ID key in a restricted REDCap project before S3 upload, but I’d love to compare wording and workflows your IRBs have approved.